Literature DB >> 27575054

Correction: Influence of LAR and VAR on Para-Aminopyridine Antimalarials Targetting Haematin in Chloroquine-Resistance.

David C Warhurst, John C Craig, K Saki Raheem.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0160091.].

Entities:  

Year:  2016        PMID: 27575054      PMCID: PMC5005012          DOI: 10.1371/journal.pone.0162142

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


There are errors in the published article. Fig 1 does not show the enantiomeric bond from 4-amino to methyl. In the caption for Fig 1, the reference given is incorrect. The correct reference is [13]. Please see the correct Fig 1 and its caption here.
Fig 1

Structures of the main pAP compounds examined.

Note outline (blue) of the p-aminopyridine moiety in CQ(2) and its presence in Atebrin, ATB(1) and (5). Also note 2 pAP moieties in each of (3), (4) and (6). Compound (5), a half–piperaquine, has low antiparasitic activity and shows 6 times less activity in the in vitro BIHA test than PQ (3) [13].

Structures of the main pAP compounds examined.

Note outline (blue) of the p-aminopyridine moiety in CQ(2) and its presence in Atebrin, ATB(1) and (5). Also note 2 pAP moieties in each of (3), (4) and (6). Compound (5), a half–piperaquine, has low antiparasitic activity and shows 6 times less activity in the in vitro BIHA test than PQ (3) [13]. In the Physiochemical section of the Material and Methods, the third equation appears incorrectly. The correct equation is: In the Molecular Modelling sections of the Material and Methods and the Results and Discussion, the reference given is incorrect. The reference should be [25]. The references that appear at the end of the fourth paragraph in the Results and Discussion are incorrect. The correct references are [21-24]. In the last sentence of the Graphical Approaches section of the Results and Discussion the incorrect reference appears. The correct reference is [21]. There are errors in Table 1. In the LogCQRI column the value for cpd5 should be 0.308, not 1.308. In the VAR column the value for CQ should be 143482, not 1434882. The value for the first DCQ should be 4897788, not 48897788.
Table 1

Physicochemical and other parameters for the compounds studied.

antilogLAR/VAR
logD4.8logD7.4Log CQ RIlogD7.4AntilogD7.4-D4.8BHIABHIABHIA
DruglogPpKa1pKa2pKa3pKa4pHlogD(LAR/VAR)LOGLAR(res/sens)LARlogD4.8VARlogVARIC50 mMSEn
CQ4.7210.188.38-20-207.40.916681434825.1567961.30.118
CQ4.7210.188.38-20-204.8-4.24011-4.24010.916681.1498.254345.75E-05
PQ6.116.886.245.725.397.45.98833104378.25.018610.620.056
PQ6.116.886.245.725.394.80.969720.969725.988330.399734929.3266
OHPQ5.676.66.415.394.837.45.6000119874.334.2982930.580.096
OHPQ5.676.66.415.394.834.81.301721.301725.600120.17639811820.032
DCQ6.18.718.347.365.97.44.1948977886.690.610.097
DCQ6.18.718.347.365.94.8-2.5-2.54.190.17615488.20.0032
DCQa6.18.718.347.365.97.43.535863.79E+088.5791450.610.097
DCQa6.18.718.347.365.94.8-5.04328-5.04333.535860.1763434.489.05E-06
53.487.925.54-20-207.42.840811965.4763.2934683.350.339
53.487.925.54-20-204.8-0.45266-0.45272.840810.308693.1230.3526
HCQ3.8359.668.27-20-207.40.64976139607.15.144907
HCQ3.8359.668.27-20-204.8-4.49515-4.49520.649761.8984.464373.20E-05
DECQ4.3510.968.4-20-207.4-0.2514144113.85.158706
DECQ4.3510.968.4-20-204.8-5.41011-5.4101-0.25141.5640.560533.89E-06
DAQ3.318.727.53-20-207.41.6103689365.844.951172
DAQ3.318.727.53-20-204.8-3.34081-3.34081.610340.73240.77210.0005
AQ4.268.667.05-20-207.42.8234447410.074.675871
AQ4.268.667.05-20-204.8-1.85244-1.85242.823440.297665.940.014
ATB4.8510.477.12-20-207.41.5965454779.284.738616
ATB4.8510.477.12-20-204.8-3.14207-3.14211.596540.68239,49510.0007
SC5.1510.157.28-20-207.42.154468522.824.835835
SC5.1510.157.28-20-204.8-2.68144-2.68142.15440.376142.920.0021
PH2036.4510.295.57-20-207.43.553072698.943.41193
PH2036.4510.295.57-20-204.80.121880.121883.553070.1933573.321.324
  1 in total

1.  Influence of LAR and VAR on Para-Aminopyridine Antimalarials Targetting Haematin in Chloroquine-Resistance.

Authors:  David C Warhurst; John C Craig; K Saki Raheem
Journal:  PLoS One       Date:  2016-08-02       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.